ライフサイエンスコーパス: insulin-sensitizing

1 ellular reactive oxygen species required for insulin sensitizing.

2 nuclear translocation, thereby mimicking the insulin-sensitizing abilities of the hepatic ChREBP knoc

3 ocytes and the tissue-specific nature in the insulin sensitizing action of rosiglitazone, we examined

4 limited weight-lowering efficacy and minimal insulin sensitizing action.

5 racellular Ca2+ handling, independent of its insulin sensitizing action.

6 tion of SIRT1 in adipocytes induces the same insulin-sensitizing action as PPARgamma ligands.

7 first evidence that thiazolidinediones exert insulin-sensitizing action directly on pancreatic beta-c

8 we have uncovered an unexpected, neomorphic insulin-sensitizing action for exogenous non-mitogenic h

9 one leptin has profound glucose-lowering and insulin-sensitizing action in type 1 diabetic rodent mod

10 P13 in adipocytes, which correlates with the insulin-sensitizing action of CTRP13.

11 the latter being largely independent of the insulin-sensitizing action of the drug.

12 e microvasculature, which contributes to its insulin-sensitizing action.

13 SHR model, Cd36 is a key determinant of the insulin-sensitizing actions of a thiazolidinedione ligan

14 In contrast to the insulin-sensitizing actions of adiponectin in liver and

15 the Cd36 fatty acid transporter gene in the insulin-sensitizing actions of thiazolidinediones, we st

16 on animal models to delineate the receptor's insulin-sensitizing actions.

17 thazolamide (MTZ) and related compounds with insulin sensitizing activity in vitro.

18 ntification of PPARgamma ligands with robust insulin-sensitizing activity and improved tolerance amon

19 thesis of new RXR modulators that retain the insulin-sensitizing activity of RXR agonists but produce

20 The insulin-sensitizing activity points to a more central ro

21 t in a manner that leads to retention of the insulin-sensitizing activity that is characteristic of f

22 believed that thiazolidinediones exert their insulin-sensitizing activity through activation of perox

23 diabetes is wide and consists of agents with insulin-sensitizing activity, agents that stimulate insu

24 glypican-4 (GPC4) has been identified as an insulin-sensitizing adipokine serving as a marker for bo

25 igated the effect of iron on adiponectin, an insulin-sensitizing adipokine that is decreased in diabe

26 C1q/TNF-related protein-12 (CTRP12), a novel insulin-sensitizing adipokine that regulates glucose met

27 of Fam132a, which encodes a newly identified insulin-sensitizing adipokine, adipolin, is significantl

28 cluding a reduction in the expression of the insulin-sensitizing adipokine, adiponectin.

29 expression in beta-cells and Adiponectin, an insulin-sensitizing adipokine, in adipocytes; in vivo os

30 erminants of blood levels of adiponectin, an insulin-sensitizing adipokine.

31 n summary, glypican-4 is a novel circulating insulin sensitizing adipose-derived factor that, unlike

32 Troglitazone, an insulin sensitizing agent, reduces glucose concentration

33 We additionally hypothesized that an insulin-sensitizing agent (rosiglitazone) would prevent

34 hese results indicate that treatment with an insulin-sensitizing agent can lead to improvement in bio

35 This prospective study evaluates the role of insulin-sensitizing agent in treatment of NASH.

36 h returned to normal upon treatment with the insulin-sensitizing agent pioglitazone.

37 tazone, like other thiazolidinediones, is an insulin-sensitizing agent that activates the peroxisome

38 Rosiglitazone is an insulin-sensitizing agent that has recently been shown t

39 atment of normal (nondiabetic) pigs with the insulin-sensitizing agent troglitazone improves recovery

40 Troglitazone is a new insulin-sensitizing agent used to treat type 2 diabetes

41 Metformin is an insulin-sensitizing agent with potent antihyperglycemic

42 Farglitazar (GI262570), an insulin-sensitizing agent, selectively binds and activat

43 Troglitazone (TRO), a novel insulin-sensitizing agent, significantly lowers blood pr

44 s and then 4 mg twice daily for 8 weeks), an insulin-sensitizing agent, was given to 7 insulin-resist

45 primarily focused on weight loss and use of insulin sensitizing agents, including the thiazolidenedi

46 ediones, pioglitazone and rosiglitazone, are insulin sensitizing agents, that are licensed for the ma

47 the intracellular targets of a new class of insulin sensitizing agents, the thiazolidinediones.

48 Novel insulin sensitizing agents, thiazolidinediones, have bee

49 s have demonstrated the potential utility of insulin-sensitizing agents and lipid-lowering therapies

50 by thiazolidinediones (TZDs), widely used as insulin-sensitizing agents for the treatment of type 2 d

51 ith hyperinsulinemia and insulin-resistance, insulin-sensitizing agents might be beneficial.

52 ce all PPARgamma agonists were orally active insulin-sensitizing agents producing reductions of eleva

53 is and is the molecular target of a class of insulin-sensitizing agents used for the management of ty

54 iazolidinediones (TZDs) are a novel class of insulin-sensitizing agents used in the treatment of NIDD

55 estrogen-progestin oral contraceptives, (3) insulin-sensitizing agents, and (4) estrogen-progestin f

56 Newer therapies, such as insulin-sensitizing agents, are beneficial in correcting

57 compounds, as well as a subclass of non-TZD insulin-sensitizing agents, have been shown to be peroxi

58 ance that is distinct from commonly utilized insulin-sensitizing agents, the inhibitor promoted insul

59 A novel class of insulin-sensitizing agents, the thiazolidinedines (TZDs)

60 zone) and troglitazone are thiazolidinedione insulin-sensitizing agents, which are undergoing clinica

61 int to evaluate and perhaps develop improved insulin-sensitizing agents.

62 skewing differentiation of macrophages into insulin-sensitizing, alternatively activated M2 macropha

63 ega-3 FA receptor/sensor and mediates potent insulin sensitizing and antidiabetic effects in vivo by

64 s through lifestyle modifications as well as insulin sensitizing and antioxidant medications may be o

65 iponectin, a vasculoprotective molecule with insulin-sensitizing and anti-atherogenic properties, sup

66 Adiponectin is an insulin-sensitizing and anti-inflammatory fat cell hormo

67 Adiponectin is an adipokine that exerts insulin-sensitizing and anti-inflammatory roles in insul

68 Despite extensive documentation of their insulin-sensitizing and antihyperglycemic effects, the i

69 xisome proliferator-activated receptors with insulin-sensitizing and glucose-lowering actions and fav

70 t strategies for treatment of hyperglycemia, insulin-sensitizing and insulin-providing strategies, on

71 ss-induced hormone with potent anti-obesity, insulin-sensitizing, and hepatoprotective properties.

72 We here report the unique anti-inflammatory, insulin-sensitizing, and immunity-enhancing properties o

73 Insulin sensitizing, anti-inflammatory, and antifibrotic

74 ression, but SIRT1 was dispensable for NAMPT insulin-sensitizing, anti-dyslipidemic, and light-cycle

75 Adiponectin is an adipokine with insulin-sensitizing, anti-inflammatory, and cardiac prot

76 a circulating adipocyte-derived protein, has insulin-sensitizing, anti-inflammatory, antiatherogenic,

77 been widely studied and shown to have potent insulin-sensitizing, antiapoptotic, and anti-inflammator

78 Adiponectin has insulin-sensitizing, antiatherogenic, and anti-inflammat

79 n actively pursued as the next generation of insulin-sensitizing antidiabetic drugs, because the curr

80 The thiazolidinedione class of insulin-sensitizing, antidiabetic drugs interacts with p

81 ectin, a hormone secreted by adipocytes, has insulin-sensitizing, antidiabetic, antiinflammatory, and

82 clinical studies, reveal the lipid-lowering, insulin-sensitizing, antihypertensive, and anti-inflamma

83 ormone secreted by adipose tissue that shows insulin-sensitizing, antiinflammatory, and antiatherogen

84 Metformin, an insulin-sensitizing biguanide, enhances peripheral insul

85 The insulin-sensitizing compound troglitazone has evolved in

86 he therapeutic potential of chiro-inositols, insulin-sensitizing compounds safe for human consumption

87 h that among the 12,069 treated with neither insulin-sensitizing drug (36.0%, P= or <0.0001 for both

88 his case, insulin resistance) and whether an insulin-sensitizing drug (metformin) is cardioprotective

89 ered as a binding target of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class

90 Our objective was to determine if the insulin-sensitizing drug pioglitazone acutely reduces in

91 infarction (MI) derive more benefit from the insulin-sensitizing drug pioglitazone hydrochloride comp

92 The insulin-sensitizing drug rosiglitazone also increases th

93 f insulin resistance in Zucker rats with the insulin-sensitizing drug rosiglitazone partially restore

94 were randomized to placebo (n = 133) or the insulin-sensitizing drug troglitazone (400 mg/day; n = 1

95 tection was potentiated by rosiglitazone, an insulin-sensitizing drug used to treat type 2 diabetes.

96 y investigates whether the widely prescribed insulin-sensitizing drug, metformin (Glucophage(R)), aff

97 Upon treatment with rosiglitazone, an insulin-sensitizing drug, these macrophage-originated ge

98 4 levels are normalized by rosiglitazone, an insulin-sensitizing drug.

99 the target of the thiazolidinedione class of insulin sensitizing drugs.

100 We investigated the effects of two insulin-sensitizing drugs (metformin and rosiglitazone)

101 Thiazolidinediones (TZDs) are insulin-sensitizing drugs and are potent agonists of the

102 The thiazolidinedione (TZD) insulin-sensitizing drugs and peroxisome proliferator-ac

103 bers of the thiazolidinedione (TZD) class of insulin-sensitizing drugs are extensively used in the tr

104 ggests that Gpr120 agonists could become new insulin-sensitizing drugs for the treatment of type 2 di

105 Insulin-sensitizing drugs of the thiazolidinedione class

106 PPARgamma is a target for insulin-sensitizing drugs such as glitazones, which impr

107 oved thiazolidinediones (TZDs) are effective insulin-sensitizing drugs that may have efficacy for tre

108 The insulin-sensitizing drugs thiazolidinediones (TZDs) are

109 ts, "such as thiazolidinediones-" a class of insulin-sensitizing drugs, have been reported to cause a

110 o the functional receptor for a new class of insulin-sensitizing drugs, the thiazolidinediones, now w

111 rget of the thiazolidinedione (TZD) class of insulin-sensitizing drugs, which have been widely prescr

112 se homeostasis, and is a molecular target of insulin-sensitizing drugs.

113 receptor for the thiazolidinedione class of insulin-sensitizing drugs.

114 receptor for the thiazolidinedione class of insulin-sensitizing drugs.

115 perties of Claramine are consistent with its insulin sensitizing effect.

116 In obese subjects, this insulin-sensitizing effect could not be detected.

117 Harmine is a natural compound possessing insulin-sensitizing effect in db/db diabetic mice.

118 ted beta-oxidation in muscle cells exerts an insulin-sensitizing effect independently of changes in i

119 knockout mice, we demonstrate that the Sesn3 insulin-sensitizing effect is largely independent of AMP

120 This insulin-sensitizing effect is specific for GIP because i

121 sphorylation site (TSC2S1345A) inhibited the insulin-sensitizing effect of adiponectin in C2C12 cells

122 expression of LKB1 in HeLa cells rescued the insulin-sensitizing effect of adiponectin.

123 not dominant-negative p38 MAPK, reduced the insulin-sensitizing effect of adiponectin.

124 eptor substrate (IRS)-1 is essential for the insulin-sensitizing effect of CR, we measured in vitro 2

125 insulin-induced signaling that mediates the insulin-sensitizing effect of exercise and contractions

126 We conclude that the mechanism for the insulin-sensitizing effect of troglitazone, but not metf

127 A similar insulin-sensitizing effect was seen upon treatment of ob

128 The consequent insulin-sensitizing effect within skeletal muscle lowere

129 tance in mice while also having an opposite, insulin-sensitizing effect, accompanied by reduced tissu

130 a signaling is also required for the hepatic insulin sensitizing effects of TZDs.

131 ing with BAM15 has powerful anti-obesity and insulin sensitizing effects without compromising lean ma

132 O mice are refractory to both the beneficial insulin-sensitizing effects and the detrimental weight g

133 between adiponectin multimerization and its insulin-sensitizing effects has been demonstrated, sugge

134 betic thiazolidinediones (TZDs), which exert insulin-sensitizing effects in adipose tissue, skeletal

135 has attracted much attention because of its insulin-sensitizing effects in liver and skeletal muscle

136 These insulin-sensitizing effects in mice and human myotubes w

137 The improved anti-inflammatory and insulin-sensitizing effects in the APPL2 hepatocyte-spec

138 ypothesis that increased shear stress exerts insulin-sensitizing effects in the vasculature and this

139 rapeutic target of the anti-inflammatory and insulin-sensitizing effects of AICAR.

140 s reveal novel mechanistic insights into the insulin-sensitizing effects of DGAT1 inhibition in mouse

141 largely unrelated to leptin action and that insulin-sensitizing effects of FABP deficiency are, at l

142 iota is necessary for, and can transmit, the insulin-sensitizing effects of PAHSAs in HFD-fed GF male

143 obesity are both likely to contribute to the insulin-sensitizing effects of regular physical activity

144 r 7 days and compared responses to the known insulin-sensitizing effects of rosiglitazone (6 mg kg(-1

145 studies are needed to determine whether the insulin-sensitizing effects of the glitazones can preven

146 lts further suggest the possibility that the insulin-sensitizing effects of the thiazolidinedione dru

147 ectin multimer may contribute to the hepatic insulin-sensitizing effects of these agents.

148 n sensitivity and this receptor mediates the insulin-sensitizing effects of thiazolidinediones (TZDs)

149 The insulin-sensitizing effects of thiazolidinediones are th

150 eptor-gamma; an action may contribute to the insulin-sensitizing effects of this class of compounds.

151 probably explained by the peripheral tissue insulin-sensitizing effects of troglitazone.

152 mega-3-FAs produce robust anti-inflammatory, insulin-sensitizing effects, both in vivo and in vitro,

153 addition to its potent glucose-lowering and insulin-sensitizing effects, rFGF1 could be therapeutica

154 ecreted by adipocytes and is thought to have insulin-sensitizing effects.

155 s and diabetes, exerts anti-inflammatory and insulin-sensitizing effects.

156 ycemic control through its peripheral tissue insulin-sensitizing effects.

157 in vivo inhibition of Ltb4r1 leads to robust insulin-sensitizing effects.

158 , such as INT131 (1), have displayed similar insulin-sensitizing efficacy as TZDs, but lack many side

159 dy weight and adiposity, while improving its insulin-sensitizing efficacy at the same time.

160 the absence of classical agonism, to derive insulin-sensitizing efficacy with improved therapeutic i

161 ng and provide a molecular mechanism for the insulin sensitizing function of adiponectin.

162 While the insulin-sensitizing function of adiponectin has been ext

163 cocorticoid-modulated insulin resistance and insulin sensitizing genes, in which EHMT2 coactivation i

164 ocorticoids also stimulate the expression of insulin-sensitizing genes, such as Irs2.

165 genes and increasing adipocyte expression of insulin-sensitizing genes.

166 The insulin sensitizing glitazone drugs, rosiglitazone (ROS)

167 in signaling and thus affect activity of the insulin-sensitizing hormone osteocalcin.

168 Adiponectin (Acrp30) is an insulin-sensitizing hormone produced and secreted exclus

169 Adiponectin is a circulating insulin-sensitizing hormone that homooligomerizes into t

170 Adiponectin, an insulin-sensitizing hormone, and resistin, known to prom

171 muscle from cross-sectional and longitudinal insulin-sensitizing intervention studies and in vitro in

172 tivity, and significantly decreased after an insulin-sensitizing intervention; increased intracellula

173 es to prevent type 2 diabetes might focus on insulin-sensitizing interventions rather than interventi

174 related to the production and release of the insulin-sensitizing lipokine palmitoleate (16:1n-7).

175 multimer of adiponectin may be an important insulin-sensitizing mechanism.

176 d through both an insulin-independent and an insulin-sensitizing mechanism.

177 LYPLAL1, showed diverse phenotypes in the 3 insulin-sensitizing mechanisms, and the first 7 of these

178 by screening IR-relevant phenotypes in the 3 insulin-sensitizing mechanisms, including adipogenesis,

179 ed into those using TZDs and those not using insulin-sensitizing medication based on prescriptions fi

180 ZDs and 1,192 (25.4%) patients not receiving insulin-sensitizing medications died (adjusted hazard ra

181 TZDs and 741 (15.8%) patients not receiving insulin-sensitizing medications required HF hospitalizat

182 iones (rosiglitazone, pioglitazone) are oral insulin-sensitizing medications used in type 2 diabetes

183 ality when compared with those not receiving insulin-sensitizing medications.

184 Adiponectin is a major insulin-sensitizing, multimeric hormone derived from adi

185 adipocytes, APOM expression was enhanced by insulin-sensitizing peroxisome proliferator-activated re

186 trials, NASH was partially attenuated by an insulin-sensitizing peroxisome proliferator-activated re

187 at evoke fewer side effects while preserving insulin-sensitizing potential.

188 es (TZDs) pioglitazone and rosiglitazone are insulin-sensitizing PPARgamma agonists used to treat typ

189 one with anti-atherogenic, anti-diabetic and insulin sensitizing properties.

190 thiazolidenediones, which are compounds with insulin-sensitizing properties in several tissues, inclu

191 plasma protein with anti-atherosclerotic and insulin-sensitizing properties that suppresses hepatic g

192 the treatment of diabetes mellitus for their insulin-sensitizing properties, but also have immunomodu

193 acid (POA), an FA with anti-inflammatory and insulin-sensitizing properties, is synthesized from palm

194 In addition to its antigluconeogenic and insulin-sensitizing properties, metformin has emerged as

195 ulate the expression of adiponectin that has insulin-sensitizing properties.

196 cid, a fatty acid with anti-inflammatory and insulin-sensitizing properties.

197 pocyte-derived hormone with antidiabetic and insulin-sensitizing properties.

198 tin, an adipokine with anti-inflammatory and insulin-sensitizing properties.

199 Because adiponectin is suspected to have insulin-sensitizing proprieties, these epigenetic adapta

200 Using mouse models, we identified the insulin-sensitizing receptor SORLA as a molecular factor

201 To determine whether insulin-sensitizing strategies induce anxiolytic- and/or

202 trast to the insulin-providing strategy, the insulin-sensitizing strategy led to (1) lower plasma ins

203 rator activated receptor gamma, are one such insulin-sensitizing therapeutic intervention in current

204 T2D and raise the possibility of developing insulin-sensitizing therapeutics based on manipulations

205 is might be a useful approach for developing insulin-sensitizing therapeutics.

206 atosis and bone loss associated with current insulin-sensitizing therapies.

207 is mechanism could lead to a new approach to insulin-sensitizing therapies.

208 Therefore, early administration of insulin-sensitizing therapy may reduce breast cancer ris

209 Insulin-sensitizing therapy mitigates the reproductive d

210 ns are increased in 3T3-L1 adipocytes by the insulin sensitizing thiazolidinedione drugs, which are a

211 Insulin-sensitizing thiazolidinedione (TZD) compounds ar

212 ma (PPARgamma) ligands, namely the synthetic insulin-sensitizing thiazolidinedione (TZD) compounds, h

213 influenced the pharmacologic efficacy of the insulin-sensitizing thiazolidinedione (TZD) rosiglitazon

214 The insulin-sensitizing thiazolidinedione pioglitazone resto

215 Insulin-sensitizing thiazolidinedione therapy normalized

216 Binding of pioglitazone, an insulin-sensitizing thiazolidinedione used in the treatm

217 Troglitazone is an insulin-sensitizing thiazolidinedione, which improves he

218 ptor-gamma (PPAR-gamma) is the target of the insulin sensitizing thiazolidinediones (TZDs), a class o

219 eptor (PPAR) gamma, the molecular target for insulin sensitizing thiazolidinediones used in patients

220 AR ligands such as fibrates (PPAR-alpha) and insulin-sensitizing thiazolidinediones (PPAR-gamma) are

221 inding certain fatty acids, eicosanoids, and insulin-sensitizing thiazolidinediones (TZD).

222 s activated by fatty acids, eicosanoids, and insulin-sensitizing thiazolidinediones (TZDs).

223 Insulin-sensitizing thiazolidinediones have shown effica

224 e CD40L (sCD40L) and that treatment with the insulin-sensitizing thiazolidinediones lowers this index

225 was elevated in obese mice and decreased by insulin-sensitizing thiazolidinediones.

226 Insulin-sensitizing treatment is sufficient to abrogate

227 t potential benefits of anti-inflammatory or insulin-sensitizing treatment strategies in healthy indi

228 The insulin-sensitizing treatment strategy led to changes in

229 arization versus initial medical therapy and insulin-sensitizing versus insulin-providing therapy on

230 PPARgamma ligands such as rosiglitazone are insulin sensitizing, yet the mechanisms remain unclear.